Written and reviewed by Kevin Nerway · Last verified 26 October 2026
Key Takeaways
- Executive Ryan Khouri acquired 10,100 shares of CTT Pharmaceutical Holdings Inc. (NASDAQ: CTTH) at $0.045 per share for a total transaction value of $454 on September 22, 2026.
- The purchase expands Khouri's total direct shareholding to 9,424,556 shares while the equity trades at $0.06, reflecting a 20% price contraction over the past six months and a 6% decline year-to-date.
- Valuations remain elevated despite recent price declines, with company analysis indicating a Price/Book ratio of 86.81 alongside an unprofitability profile over the trailing twelve-month period.
- Broad equity market benchmarks ended mixed to lower, with the Dow Jones Industrial Average dropping 1.23% to 52,215.16 and the S&P 500 falling 0.52% to 7,623.68, while the CBOE Volatility Index rose 2.21% to 19.45.
CEO Accumulation Follows Multi-Month Equity Retrenchment
Corporate disclosure reveals that Ryan Khouri, Chief Executive Officer and member of the board of directors at CTT Pharmaceutical Holdings Inc., executed an open-market acquisition of company stock on September 22, 2026. Khouri acquired 10,100 shares at a purchase price of $0.045 per share, representing a total capital investment of $454.
Following the completion of